PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were compared in patients with hormone-resistant prostate cancer (HRPC) treated with prednisone (5 mg orally, four times ...

MILAN, Italy — First-line use of abiraterone acetate (Zytiga, Janssen Biotech) with prednisone for metastatic castration-resistant prostate cancer improves radiographic progression-free survival, ...

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA Plus Prednisone CHICAGO, June 2, 2012 ...

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...

Janssen Research & Development announced updated results from the Phase 3 study of Zytiga (abiraterone acetate) plus prednisone demonstrating that it continued to provide statistically significant ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Please provide your email address to receive an email when new articles are posted on . The addition of abiraterone acetate to prednisone significantly improved survival and delayed disease ...

Credit: Getty Images. The application is supported by data from a phase 3 study evaluating niraparib plus AAP as first-line treatment in patients with mCRPC with or without alterations in HRR ...

Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer RARITAN, N.J., ...